Cafepharma Today

May 22 2025 - Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population
Prices for new US drugs doubled in 4 years as focus on rare disease grows
FDA expands warnings of heart risks on COVID shots
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Merck KGaA's Drug Tops Roche's Avastin for Colon Cancer
Bloomberg
Saturday, September 28, 2013 - 11:46am
tags:
Merck KGaA, colon cancer, Roche, Avastin, Erbitux
Lilly Disappointed in Medicare Decision to Deny Appropriate Patient Access to Beta-Amyloid Imaging Agents, Including Amyvid™ (Florbetapir F 18 Injection), Despite Support From Experts, Patients and the Alzheimer's Disease Community
Yahoo/PR NewsWire
Saturday, September 28, 2013 - 11:11am
tags:
Medicare, Eli Lilly, Amyvid
How Johnson & Johnson Plans to Win the Prostate Cancer Battle
Motley Fool
Saturday, September 28, 2013 - 11:09am
tags:
Zytiga, prostate cancer, JNJ
[video]Cramer: Biggest blockbuster drug in ages?
CNBC
Saturday, September 28, 2013 - 11:07am
tags:
Pharmacyclics, ibrutinib
[video]Should Merck Copy Pfizer and Join the "Spinoff Club"?
Motley Fool
Saturday, September 28, 2013 - 11:05am
tags:
Merck
A Promising Future For Anthera's Blisibimod
Seeking Alpha
Saturday, September 28, 2013 - 11:04am
tags:
lupus, blisibimod, Anthera
AstraZeneca Vaccine Update
Yahoo/Zacks
Saturday, September 28, 2013 - 11:02am
tags:
vaccines, flu vaccines, AstraZeneca
Bristol-Myers: Interesting Investing Opportunity With Onglyza
Seeking Alpha
Saturday, September 28, 2013 - 11:00am
tags:
type 2 diabetes, Onglyza, diabetes, Bristol-Myers Squibb, AstraZeneca
Nektar's Pain Drug Disappoints
Yahoo/Zacks
Saturday, September 28, 2013 - 10:59am
tags:
pain management, NKTR-181, Nektar
Bristol’s Yervoy Adds Up to 10 Years of Life for Cancer Patients
Bloomberg
Saturday, September 28, 2013 - 10:57am
tags:
Yervoy, Bristol-Myers Squibb
Synta Announces Presentation of Ganetespib Results at the 2013 European Cancer Congress
Yahoo/BusinessWire
Saturday, September 28, 2013 - 10:55am
tags:
Synta Pharmaceuticals, lung cancer, ganetespib
Arno Therapeutics to Present Data Validating Target Biomarker at European Cancer Congress 2013
Yahoo/Globe Newswire
Saturday, September 28, 2013 - 10:52am
tags:
onapristone, breast cancer, biomarkers, Arno Therapeutics
ImmunoGen, Inc. Announces Results from Kadcyla® Phase III Trial, TH3RESA, Being Presented Today at the European Cancer Congress
Yahoo/BusinessWire
Saturday, September 28, 2013 - 10:46am
tags:
Roche, Kadcyla, Immunogen, breast cancer
Exelixis Announces Presentation of Updated Phase 1b Data for Cobimetinib (GDC-0973/XL518) in Combination with Vemurafenib at ECC 2013
Yahoo/BusinessWire
Saturday, September 28, 2013 - 10:44am
tags:
metastatic melanoma, melanoma, Exelixis, Cobimetinib
ARIAD Presents Updated Phase 1/2 Data on AP26113 in Patients with Non-Small Cell Lung Cancer
Yahoo/BusinessWire
Saturday, September 28, 2013 - 10:42am
tags:
non-small cell lung cancer, Ariad Pharmaceuticals, AP26113
Phase 3 Trial Comparing Vectibix® (Panitumumab) to Erbitux® (Cetuximab) Meets Primary Endpoint Of Non-Inferiority Of Overall Survival
Yahoo/PR NewsWire
Saturday, September 28, 2013 - 10:41am
tags:
Vectibix, colorectal cancer, Amgen
For Arena, Belviq Refills Are Becoming Key
Seeking Alpha
Saturday, September 28, 2013 - 10:39am
tags:
Belviq, Arena Pharmaceuticals
The Rosen Law Firm Announces Investigation of Shareholder Securities Claims Against Prosensa Holding NV – RNA
Yahoo/BusinessWire
Saturday, September 28, 2013 - 10:38am
tags:
Prosensa, lawsuits
Does a Lack of Interest Tell You This Biotech Has Limited Upside?
Motley Fool
Saturday, September 28, 2013 - 10:36am
tags:
Clovis Oncology
Jazz Pharmaceuticals Stares At Generic Threat, Thrives
investors.com
Saturday, September 28, 2013 - 10:34am
tags:
Jazz Pharmaceuticals, generics

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.